BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET
1. BridgeBio will host an investor webinar on September 10, 2025. 2. Dr. Gafni will discuss ADH1 and the encaleret treatment. 3. Topline results for CALIBRATE Phase 3 trial expected in fall 2025. 4. Webinar will include executive reviews of ongoing clinical development.